23.30
5.21%
-1.28
After Hours:
23.00
-0.30
-1.29%
Bicycle Therapeutics Plc ADR stock is currently priced at $23.30, with a 24-hour trading volume of 424.08K.
It has seen a -5.21% decreased in the last 24 hours and a +2.51% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $24.87 pivot point. If it approaches the $23.27 support level, significant changes may occur.
Previous Close:
$24.58
Open:
$24.8
24h Volume:
424.08K
Market Cap:
$887.10M
Revenue:
$26.98M
Net Income/Loss:
$-180.66M
P/E Ratio:
-4.9786
EPS:
-4.68
Net Cash Flow:
$-63.56M
1W Performance:
-0.47%
1M Performance:
+2.51%
6M Performance:
+58.61%
1Y Performance:
+7.18%
Bicycle Therapeutics Plc ADR Stock (BCYC) Company Profile
Name
Bicycle Therapeutics Plc ADR
Sector
Industry
Phone
44 1223 497 415
Address
Babraham Research Campus, Building 900, Cambridge
Bicycle Therapeutics Plc ADR Stock (BCYC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-11-23 | Upgrade | B. Riley Securities | Neutral → Buy |
Aug-31-22 | Initiated | Cowen | Outperform |
Jul-28-22 | Initiated | Barclays | Overweight |
Jul-06-22 | Resumed | Canaccord Genuity | Buy |
Apr-13-22 | Downgrade | B. Riley Securities | Buy → Neutral |
Apr-07-22 | Resumed | Cantor Fitzgerald | Overweight |
Feb-14-22 | Initiated | Morgan Stanley | Equal-Weight |
Dec-17-21 | Initiated | SVB Leerink | Outperform |
Dec-09-21 | Initiated | Needham | Buy |
Sep-30-21 | Initiated | B. Riley Securities | Buy |
Apr-20-21 | Initiated | JMP Securities | Mkt Outperform |
Oct-12-20 | Initiated | Cantor Fitzgerald | Overweight |
Jun-12-20 | Initiated | Oppenheimer | Outperform |
Apr-17-20 | Initiated | H.C. Wainwright | Buy |
Nov-14-19 | Initiated | ROTH Capital | Buy |
Sep-11-19 | Upgrade | Goldman | Neutral → Buy |
Jun-17-19 | Initiated | Canaccord Genuity | Buy |
Jun-17-19 | Initiated | Goldman | Neutral |
Jun-17-19 | Initiated | Jefferies | Buy |
Jun-17-19 | Initiated | Piper Jaffray | Overweight |
View All
Bicycle Therapeutics Plc ADR Stock (BCYC) Latest News
Bicycle Therapeutics (BCYC) Moves to Buy: Rationale Behind the Upgrade
Zacks Investment Research
Wall Street Analysts See a 77.22% Upside in Bicycle Therapeutics (BCYC): Can the Stock Really Move This High?
Zacks Investment Research
Expert Ratings For Bicycle Therapeutics
Benzinga
Walmart To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga
The Analyst Landscape: 4 Takes On Bicycle Therapeutics
Benzinga
Forecasting The Future: 4 Analyst Projections For Bicycle Therapeutics
Benzinga
Bicycle Therapeutics Plc ADR Stock (BCYC) Financials Data
Bicycle Therapeutics Plc ADR (BCYC) Revenue 2024
BCYC reported a revenue (TTM) of $26.98 million for the quarter ending December 31, 2023, a +86.52% rise year-over-year.
Bicycle Therapeutics Plc ADR (BCYC) Net Income 2024
BCYC net income (TTM) was -$180.66 million for the quarter ending December 31, 2023, a -60.28% decrease year-over-year.
Bicycle Therapeutics Plc ADR (BCYC) Cash Flow 2024
BCYC recorded a free cash flow (TTM) of -$63.56 million for the quarter ending December 31, 2023, a +39.53% increase year-over-year.
Bicycle Therapeutics Plc ADR (BCYC) Earnings per Share 2024
BCYC earnings per share (TTM) was -$5.13 for the quarter ending December 31, 2023, a -35.00% decline year-over-year.
Bicycle Therapeutics Plc ADR Stock (BCYC) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Lee Kevin | CHIEF EXECUTIVE OFFICER |
Apr 03 '24 |
Sale |
23.81 |
3,158 |
75,192 |
387,270 |
Crockett Nigel | CHIEF BUSINESS OFFICER |
Apr 03 '24 |
Sale |
23.81 |
955 |
22,739 |
47,761 |
Milnes Alistair | CHIEF OPERATING OFFICER |
Apr 03 '24 |
Sale |
23.81 |
955 |
22,739 |
72,241 |
Skynner Michael | CHIEF TECHNOLOGY OFFICER |
Apr 03 '24 |
Sale |
23.81 |
955 |
22,739 |
94,884 |
Keen Nicholas | CHIEF SCIENTIFIC OFFICER |
Apr 03 '24 |
Sale |
23.81 |
790 |
18,810 |
62,803 |
Thompson Travis Alvin | CHIEF ACCOUNTING OFFICER |
Apr 03 '24 |
Sale |
23.81 |
152 |
3,619 |
23,223 |
Lee Kevin | Chief Executive Officer |
Jan 03 '24 |
Sale |
17.50 |
8,703 |
152,302 |
390,428 |
Crockett Nigel | Chief Business Officer |
Jan 03 '24 |
Sale |
17.50 |
2,643 |
46,252 |
48,716 |
Skynner Michael | Chief Technology Officer |
Jan 03 '24 |
Sale |
17.50 |
2,643 |
46,252 |
95,839 |
Milnes Alistair | Chief Operating Officer |
Jan 03 '24 |
Sale |
17.50 |
2,643 |
46,252 |
73,196 |
About Bicycle Therapeutics Plc ADR
Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in preclinical studies targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage, as well as systemically-delivered activators. In addition, it is developing THR-149, a key immune cell co-stimulatory molecule that is in Phase I clinical trials. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, hematology, ophthalmology, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; and research collaboration agreement with Bioverativ Inc., AstraZeneca AB, and Oxurion NV. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Cap:
|
Volume (24h):